EpiPen Rebates Help Middlemen, Not Patients, Justices Told
An allergy nonprofit is backing Sanofi-Aventis' bid for a U.S. Supreme Court review of lower court decisions holding it cannot pursue allegations that Mylan anticompetitively blocked a potential competitor to the...To view the full article, register now.
Already a subscriber? Click here to view full article